Genmab and Johnson & Johnson’s Darzalex Dazzles in Multiple Myeloma Trial

Genmab and Johnson & Johnson’s Darzalex Dazzles in Multiple Myeloma Trial

Source: 
BioSpace
snippet: 

Denmark-based Genmab A/S released topline data from its Phase III MAIA trial of a drug it licensed to Johnson & Johnson’s Janssen, Darzalex (daratumumab). The drug is being evaluated in combination with Celgene’s Revlimid (lenalidomide) and dexamethasone (DRd), compared to Revlimid and dexamethasone alone in patients newly diagnosed with multiple myeloma who are not candidates for high-dose chemotherapy and autologous stem cell transplant.